1.
op Bruinink DH, Oliva S, Rihova L, Schmitz A, Gilestro M, te Marvelde J, Kralova R, Høholt H, Broijl A, Johnsen HE, Hajek R, Boccadoro M, Sonneveld P, Omedè P, van der Velden VH. Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. haematol [Internet]. 2020Oct.5 [cited 2021May7];106(5):1496-9. Available from: https://haematologica.org/article/view/haematol.2020.267831